Medical Device and Diagnostics
News & Jobs
Search the Site
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login  
Medical Device Companies | Diagnostic Companies | Organizations | Search Profiles
 Company Profile


National Cancer Institute (NCI) 

NCI Public Inquiries Office
Building, 31, Room 10A03
31 Center Drive, MSC 2

Bethesda  Maryland  20892-2580  U.S.A.
Phone: 301-435-3848 Fax:



Maxygen, Inc. 

Genzyme General 

PanVera LLC 

Panacos Pharmaceuticals Inc.  Panacos has a CRADA with leading scientists at the National Cancer Institute to study the mechanism of HIV maturation inhibitors and to discover new antiviral drugs.

 Company News
Telik, Inc. (TELK) Receives $1.5 Million National Cancer Institute Contract To Develop Novel Antibody-Based PET Imaging Agent For Pancreatic Cancer 8/25/2014 8:59:52 AM
National Cancer Institute Awards $7.3 Million To Kaiser Permanente For Cancer Clinical Trials, Patient Care Research 8/4/2014 6:47:49 AM
Human Metabolome Technologies Joins National Cancer Institute's OSTR Subsidy Program 7/7/2014 10:05:53 AM
PeptiMed Signs Agreement With National Cancer Institute to Assess Safety of HelpTM Drug Delivery Nanoparticle Formulations 6/23/2014 11:43:13 AM
Amgen (AMGN) Joins The National Cancer Institute And Research Partners To Help Accelerate Development Of Personalized Treatment Approaches For Squamous Cell Lung Cancer 6/17/2014 9:59:39 AM
Data Published By Researchers At The National Cancer Institute Further Identifies How Advaxis, Inc.'s Lm-LLO Immunotherapy Eradicates Tumors 6/4/2014 9:01:53 AM
Scientists Prime The Immune System As A Powerful Cancer Weapon, National Cancer Institute Reveals 6/2/2014 7:52:47 AM
Intensity Therapeutics, Inc. Awarded Cooperative Research And Development Agreement From National Cancer Institute 5/28/2014 9:26:21 AM
Lion Biotechnologies, Inc.' Lead Program With National Cancer Institute Demonstrates Positive Results In Patients With Stage 4 Metastatic Melanoma 4/7/2014 3:25:15 PM
Syndax Pharmaceuticals Inc. Announces National Cancer Institute And FDA Reach Agreement On A Special Protocol Assessment (SPA) For The Phase 3 Trial Of Entinostat In Patients With Advanced ER+ Breast Cancer 2/13/2014 11:29:41 AM